^
    1d
    A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2026 --> May 2026
    Enrollment closed • Trial primary completion date
    |
    Tazverik (tazemetostat)
    1d
    D7400C00006: A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=226, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD19 positive
    |
    surovatamig (AZD0486)
    1d
    Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered mosunetuzumab in participants with systemic lupus erythematosus. (PubMed, Lupus Sci Med)
    Mosunetuzumab demonstrated dose-dependent peripheral B-cell depletion and a safety profile consistent with prior studies in follicular lymphoma. Based on these data, mosunetuzumab is currently being evaluated in a phase II study in severe SLE (NCT07598396).
    PK/PD data • Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    Lunsumio (mosunetuzumab-axgb)
    1d
    19-C-0116: Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=132, Recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2030 --> Mar 2031 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib)
    1d
    Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma (clinicaltrials.gov)
    P1, N=77, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    2d
    ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies (clinicaltrials.gov)
    P1, N=42, Active, not recruiting, Acepodia Biotech, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2025 --> Jul 2026
    Enrollment closed • Trial primary completion date • First-in-human
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • ACE1831
    2d
    Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=37, Suspended, David Bond, MD | Recruiting --> Suspended
    Trial suspension
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    carboplatin • lenalidomide • cyclophosphamide • ifosfamide • etoposide IV • Monjuvi (tafasitamab-cxix)
    3d
    Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov)
    P2, N=11, Terminated, University of Washington | N=20 --> 11 | Trial completion date: Jul 2028 --> May 2026 | Recruiting --> Terminated | Trial primary completion date: Dec 2027 --> May 2026; The trial closed early due to slow accrual.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Zynlonta (loncastuximab tesirine-lpyl) • AMG 211
    3d
    Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy (clinicaltrials.gov)
    P2, N=34, Recruiting, University of California, Davis | Trial completion date: Apr 2029 --> Jan 2029 | Trial primary completion date: Feb 2029 --> Oct 2028
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Ordspono (odronextamab)
    6d
    BELLWAVE-001: A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) (clinicaltrials.gov)
    P1/2, N=190, Active, not recruiting, ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2026 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    nemtabrutinib (MK-1026)
    6d
    Relyage: Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=1, Completed, Centre Hospitalier Universitaire, Amiens | Recruiting --> Completed | N=114 --> 1
    Trial completion • Enrollment change
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • lenalidomide
    6d
    Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma (clinicaltrials.gov)
    P3, N=93, Completed, Celgene | Active, not recruiting --> Completed
    Trial completion
    |
    PD-1 (Programmed cell death 1) • BCL6 (B-cell CLL/lymphoma 6) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • ICOS (Inducible T Cell Costimulator) • MME (Membrane Metalloendopeptidase)
    |
    gemcitabine • romidepsin • Onureg (azacitidine oral)